Product Data Sheet

Vicenin 2

 Cat. No.:
 HY-N2165

 CAS No.:
 23666-13-9

 Molecular Formula:
 C₂₇H₃₀O₁₅

Molecular Weight: 594.52

Target: Angiotensin-converting Enzyme (ACE)

Pathway: Metabolic Enzyme/Protease

Storage: 4°C, protect from light

* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

SOLVENT & SOLUBILITY

In Vitro DMSO: 33.33 mg/mL (56.06 mM; Need ultrasonic)

H₂O: < 0.1 mg/mL (ultrasonic) (insoluble)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.6820 mL	8.4101 mL	16.8203 mL
	5 mM	0.3364 mL	1.6820 mL	3.3641 mL
	10 mM	0.1682 mL	0.8410 mL	1.6820 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.21 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.21 mM); Clear solution

BIOLOGICAL ACTIVITY

Description Vicenin 2, a flavonoid, is an orally active angiotensin-converting enzyme (ACE) inhibitor (IC₅₀ of 43.83 μM)^[1]. Vicenin 2 has radioprotective, anti-nociceptive effects, anti-glycation anti-inflammatory, antioxidant, anticancer, antiangiogenic

properties^{[2][3]}.

In Vitro Vicenin 2 (10-100 μM; 24 hours) shows cytotoxic effect in a dose-dependent manner in NCI⊠H23 cells. Vicenin 2 increases

caspase-3 activity, increases DNA fragmentation, increasesd the levels of Rad50 and lowers levels of MMP-2 and p21 proteins while being non-toxic and radioprotective to the fibroblast cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	NCI-H23 cells
Concentration:	10 μΜ, 20 μΜ, 30 μΜ, 40 μΜ, 50 μΜ, 60 μΜ, 70 μΜ, 80 μΜ, 90 μΜ, 100 μΜ
Incubation Time:	24 hours
Result:	Showed cytotoxic effect on NCI⊠H23 cells.

In Vivo

Vicenin 2 (50 mg/kg; orally administration; for 7 days) effectively reduces the MPO activity, attenuates the expression of proinflammatory cytokines and key inflammatory markers, in DSS-induced colitis mice $^{[3]}$.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6J mice (25 g) treated with Dextran sulfate sodium (DSS) ^[3]	
Dosage:	50 mg/kg	
Administration:	Orally administration; for 7 days	
Result:	Effectively suppressed DSS-induced colitis by attenuating expressions of key inflammatory mediators.	

CUSTOMER VALIDATION

- Resour Conserv Recycl. January 2023, 106722.
- Planta Med. 2021 Feb 5.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Taranga Jyoti Baruah, et al. Vicenin-2: a potential radiosensitizer of non-small cell lung cancer cells. Mol Biol Rep. 2018 Oct;45(5):1219-1225.
- [2]. Yuti Yin, et al. Anti-inflammatory effects of Vicenin-2 on dextran sulfate sodium-induced colitis in mice. Drug Dev Res. 2019 Aug;80(5):546-555.
- [3]. Zhang YQ, et al. Bioassay-guided preparative separation of angiotensin-converting enzyme inhibitory C-flavone glycosides from Desmodium styracifolium by recycling complexation high-speed counter-current chromatography. J Pharm Biomed Anal. 2015 Jan;102:276-81.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA